FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

<p>A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence ≥ 56 days with roxadustat vs. placebo (36.1% vs 11.5%; p=0.047ǂ). Dr. Moshe Mittelman’s presentation was selected for the “2024 Highlights of ASH” SAN FRANCISCO, Dec. 09, 2023 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: […]</p>
<p>The post <a href="https://forextv.com/top-news/fibrogen-presents-data-from-phase-3-matterhorn-trial-of-roxadustat-in-patients-with-anemia-of-lower-risk-transfusion-dependent-myelodysplastic-syndromes-at-american-society-of-hematology-annual-meetin/">FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>